Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents

Journal of Medical Investigation

Volumn 60, Issue 1-2, 2013, Pages 77-90

  Yuasa, Shino ^a   Yamaguchi, Harutaka ^a   Nakanishi, Yoshinori ^a   Kawaminami, Shingo ^a   Tabata, Ryo ^a   Shimizu, Nobuhiko ^a   Kohno, Mitsuhiro ^a   Shimizu, Teruki ^b   Miyata, Junya ^c   Nakayama, Mayuko ^d   Kishi, Jun ^a   Toyoda, Yuko ^a   Nishioka, Yasuhiko ^a   Tani, Kenji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Toyo Hospital   (Japan)

^c Miyoshi Municipal Mino Hospital   (Japan)

^d Hanoura Hospital of Orthopedics and Internal Medicine   (Japan)

Author keywords

Biological agents; DAS28; Predictors; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB;

ADULT; ARTICLE; CONTINUOUS INFUSION; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERSTITIAL PNEUMONIA; JOINT SWELLING; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PNEUMONIA; PREDICTION; REMISSION; RHEUMATOID ARTHRITIS; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84876069434     PISSN: 13431420     EISSN: 13496867     Source Type: Journal    
DOI: 10.2152/jmi.60.77     Document Type: Article

References (57)

1. Lee DM, Weinblatt ME: Rheumatoid arthritis. Lancet 358: 903-911, 2001
2. Liu M, Huang Y, Hu L, Liu G, Hu X, Liu D Yang X: Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnology 12: 68, 2012. [Epub ahead of print]
3. Brennan FM, McInnes IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545, 2008
4. Senolt L, Vencovsḱy J, Pavelka K, Ospelt C, Gay S: Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 9: 102-107, 2009
5. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D: Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50: 3432-3443, 2004
6. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52: 3381-3390, 2005
7. Arntz OJ, Geurts J, Veenbergen S, Bennink MB, van den Brand BT, Abdollahi-Roodsaz S, van den Berg WB, van de Loo FA: A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritis. Arthritis Res Ther 12: R61, 2010
8. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37, 2006
9. Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, Ferraccioli G: TNF-FFblockade induces a reversible but transient effect on endothelial dysfunction in patients with longstanding severe rheumatoid arthritis. Clin Rheumatol 27: 833-839, 2008
10. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair EW: Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group: Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68: 823-827, 2009
11. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675-681, 2004
12. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS: Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2012 May 19. [Epub ahead of print]
13. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y: Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 34: 321-325, 1995
14. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA: Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32: 1-7, 2003
15. Straub RH, Müller-Ladner U, Lichtinger T, Schölmerich J, Menninger H, Lang B: Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with diseasemodifying anti-rheumatic drugs. Br J Rheumatol 36: 1298-1303, 1997
16. Alten R: Tocilizumab: a novel humanized antiinterleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis. Ther Adv Musculoskelet Dis 3: 133-149, 2011
17. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M: American College of Rheumatology; European League Against Rheumatism: American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63: 573-586, 2011
18. van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, Hazes JM, van Schaardenburg D, Breedveld FC, Dijkmans BA, Allaart CF: Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 68: 1153-1158, 2009
19. Schoels M, Aletaha D, Smolen JS, Wong JB: Comparative effectiveness and safety of biological treatment options after tumour necrosis factor ttinhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise metaanalysis. Ann Rheum Dis 71: 1303-1308, 2012
20. Papagoras C, Voulgari PV, Drosos AA: Strategies after the failure of the first anti-tumor necrosis factor-ffagent in rheumatoid arthritis. Autoimmun Rev 9: 574-582, 2010
21. Nishimoto N, Ito K, Takagi N: Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five longterm extensions. Mod Rheumatol 20: 222-32, 2010
22. Doan QV, Chiou CF, Dubois RW: Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 12: 555-569, 2006
23. Wallis RS: Tumor necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8: 601-611, 2008
24. Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N: Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod Rheumatol 2012 Oct 26. [Epub ahead of print]
25. Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, Khanna D, Greenberg JD, Furst DE: Men are significantly more likely than women to achieve sustained remission in the CORRONA Cohort of rheumatoid arthritis patients. Arthritis Care Res 10: 1002, 2012
26. Schabert VF, Bruce B, Ferrufino CF, Globe DR, Harrison DJ, Lingala B, Fries JF: Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin 28: 569-580, 2012
27. Huang X, Gu NY, Fox KM, Harrison DJ, Globe D: Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 26: 1637-1645, 2010
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger Jr TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder SR, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988
29. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T: RISING study: Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 19: 478-487, 2009
30. Miyasaka N, Takeuchi T, Eguchi K: Guidelines for the proper use of etanercept in Japan. Mod Rheumatol 16: 63-67, 2006
31. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor-aamonoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48: 35-45, 2003
32. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, Saito T, Yamamura M, Matsubara T, Miyasaka N: Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19: 351-357, 2009
33. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N: Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 66: 407-409, 2007
34. Balasundram S, Wan Mustafa WM, Ip J, Adnan TH, Supramaniam P: Conservative neck dissection in oral cancer patients: a 5 year retrospective study in Malaysia. Asian Pac J Cancer Prev 13: 4045-4050, 2012
35. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364: 263-269, 2004
36. Hyrich KL, Watson KD, Silman AJ, Symmons DP: British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-RRtherapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45: 1558-1565, 2006
37. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Ostergaard M: All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62: 22-32, 2010
38. Buch MH, Bingham SJ, Bryer D, Emery P: Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 46: 1153-1156, 2007
39. Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, Saito K, Sekiguchi N, Sato E, Kameda H, Iwata S, Mochizuki T, Amano K, Tanaka Y: Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol 18: 447-454, 2008
40. Kristensen LE, Saxne T, Geborek P: The LUNDEX: a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 54: 600-606, 2006
41. Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P: Improvements in healthrelated quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford) 51: 1860-1869, 2012
42. Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G: Gruppo Italiano di Studio sulle Early Arthritides (GISEA): Longterm retention of tumor necrosis factor-ffinhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39: 1179-1184, 2012
43. Yoshida K, Tokuda Y, Oshikawa H, Utsunomiya M, Kobayashi T, Kimura M, Deshpande GA, Matsui K, Kishimoto M: An observational study of tocilizumab and TNF-o inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology (Oxford) 50: 2093-2099, 2011
44. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959-3964, 2008
45. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A: Swiss Clinical Quality Management Physicians: Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61: 560-568, 2009
46. Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L: TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 74: 148-154, 2007
47. Takeuchi T, Kameda H: The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 6: 644-652, 2010
48. Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Goto A, Fukuda T, Matsuoka N, Ueki Y, Tsukada T, Migita K, Shoumura F, Kawabe Y, Shibatomi K, Mine M, Ida H, Origuchi T, Aoyagi K, Eguchi K: Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol 19: 488-492, 2009
49. Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P: Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47: 495-499, 2008
50. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD: Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res 63: 856-864, 2011
51. Finckh A, Liang MH, van Herckenrode CM, de Pablo P: Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum 55: 864-872, 2006
52. Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH: Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 35: 1737-1744, 2008
53. van der Kooi E, Klarenbeek NB, Güler-Yüksel M, Kerstens PJ, van der Lubbe PA, Westedt ML, ten Wolde S, Huizinga TW, Dijkmans BA, Allaart CF: A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study. Ann Rheum Dis 70: 168-171, 2011
54. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T: Japan Biological Agent Study Integrated Consortium: Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy. Mod Rheumatol 20: 531-538, 2010
55. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, Han KH, Speyer I, van der Lubbe PA, Seys PE, Breedveld FC, Dijkmans BA: Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis 66: 1227-1232, 2007
56. Scarpato S, Antivalle M, Favalli EG, Nacci F, Frigelli S, Bartoli F, Bazzichi L, Minisola G, Matucci Cerinic M: RIVIERA co-authors. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 49: 289-294, 2010
57. Chilton F, Collett RA: Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 6: 1-14, 2008